Zypadhera ® (olanzapin)

För fullständig produktresumé för Zypadhera® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

ZypAdhera® (olanzapinpamoat): Användning hos patienter med COVID-19 (Coronavirus disease 2019)

Användningen av olanzapinpamoat hos patienter med COVID-19 har inte studerats.

Detailed Information

Coronavirus disease 2019 (COVID-19) is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of olanzapine long-acting injection in patients with COVID-19 nor in patients at risk of contracting COVID-19.

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a patient with olanzapine long-acting injection who has confirmed or suspected COVID-19.

Warnings and Precautions

Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients

  • receiving medicines known to cause neutropenia, in patients with

  • with a history of drug-induced bone marrow depression/toxicity, 

  • with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and 

  • with hypereosinophilic conditions or with myeloproliferative disease.2

Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly.2

In addition, please note the following common adverse events (≥ 1/100 to < 1/10) that may occur in patients being treated with olanzapine pamoate. The following list includes adverse reactions observed from spontaneous reporting and in clinical trials. For full list of undesirable effects, please refer to section 4.8 of the ZypAdhera Summary of Product Characteristics.

General disorders

  • Asthenia (common)

  • Fatigue (common)

  • Pyrexia (common) (As assessed by measured values from clinical trials in the Olanzapine Integrated Database.)2

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. Accessed March 11, 2020.

2. ZypAdhera [summary of product characteristics] Eli Lilly Netherland B.V., The Netherlands.

3. Coronavirus disease (COVID-19) outbreak. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019

4. Coronavirus (COVID-19). Centers for Disease Control and Prevention. Accessed March 17, 2020. https://www.cdc.gov/coronavirus/2019-ncov/index.html

Glossary

CDC = The Center for Disease Control

Lilly = Eli Lilly and Company

WHO = World Health Organization

Datum fӧr senaste ӧversyn 2020 M03 24


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss